Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
SYRE Stock Chart & Stats
$33.47
-$0.27(-1.11%)
At close: 4:00 PM EST
$33.47
-$0.27(-1.11%)
Day’s Range― - ―
52-Week Range$10.91 - $35.31
Previous CloseN/A
Volume84.75K
Average Volume (3M)660.27K
Market Cap
$2.57B
Enterprise Value$532.42M
Total Cash (Recent Filing)$486.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Feb 26, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding77,592,130
10 Day Avg. Volume770,139
30 Day Avg. Volume660,275
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.11
Price to Sales (P/S)0.00
P/FCF Ratio-6.96
Enterprise Value/Market Cap0.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.77
Enterprise Value/Ebitda-2.99
Forecast
1Y Price Target
$57.17Price Target Upside70.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.03
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Dual Pathway StrategiesCombination data could position Spyre Therapeutics with best-in-class or first-in-class dual pathway strategies, supported by preclinical, translational, early clinical data, and competitive pharma development.
Phase II SKYLINE StudyThe design and timelines associated with Spyre Therapeutics’ Phase II SKYLINE study could put it at the forefront of dual pathway inhibition.
Pipeline PotentialSpyre Therapeutics is positioned to play a significant role in inflammatory bowel disease with its HLE mAb pipeline seen as having the potential for best-in-class monotherapy profiles.
Bears Say
Short InterestShort interest is at 18.5%.
Translational Support ChallengesTranslational support in axSpA and PsA is less robust, with conflicting TL1A patterns and lack of established animal models hindering preclinical validation.
Spyre Therapeutics News
SYRE FAQ
What was Spyre Therapeutics’s price range in the past 12 months?
Spyre Therapeutics lowest stock price was $10.91 and its highest was $35.31 in the past 12 months.
What is Spyre Therapeutics’s market cap?
Spyre Therapeutics’s market cap is $2.57B.
When is Spyre Therapeutics’s upcoming earnings report date?
Spyre Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 68 days.
How were Spyre Therapeutics’s earnings last quarter?
Spyre Therapeutics released its earnings results on Nov 04, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.761 by $0.611.
Is Spyre Therapeutics overvalued?
According to Wall Street analysts Spyre Therapeutics’s price is currently Undervalued.
Does Spyre Therapeutics pay dividends?
Spyre Therapeutics does not currently pay dividends.
What is Spyre Therapeutics’s EPS estimate?
Spyre Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does Spyre Therapeutics have?
Spyre Therapeutics has 77,592,130 shares outstanding.
What happened to Spyre Therapeutics’s price movement after its last earnings report?
Spyre Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.761. Following the earnings report the stock price went down -0.566%.
Which hedge fund is a major shareholder of Spyre Therapeutics?
Currently, no hedge funds are holding shares in SYRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spyre Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.17 (70.81% Upside)
$57.17 (70.81% Upside)
Blogger Sentiment
Bullish
SYRE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 273.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.5%
Last 30 Days ▲ 47.3%
Last 30 Days ▲ 47.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.51%
12-Months-Change
Fundamentals
Return on Equity
-32.63%
Trailing 12-Months
Asset Growth
19.83%
Trailing 12-Months
Company Description
Spyre Therapeutics
Spyre Therapeutics (SYRE) is a biotechnology company focused on developing innovative treatments for autoimmune diseases. Leveraging cutting-edge research and advanced therapeutic platforms, Spyre Therapeutics aims to address the unmet medical needs in this sector. The company's core products include novel biologics and small molecule drugs designed to modulate the immune system effectively, providing patients with improved outcomes and quality of life.
SYRE Stock 12 Month Forecast
Average Price Target
$57.17
▲(70.81% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Oculis Holding
―
Upstream Bio, Inc.
―
Ownership Overview
7.43% Insiders
19.32% Mutual Funds
45.74% Other Institutional Investors
17.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---